| 2020 | 2021 | 2022 | 2024 (projected) | Payables Turnover | 2.12 | 1.76 | 2.69 | 1.89 | Days Of Inventory On Hand | 68.95 | 70.33 | 82.61 | 0.001307 |
Is Immunoprecise Antibodies (USA Stocks:IPA) undervalued?
 | By Vlad Skutelnik | Macroaxis Story |
Immunoprecise Antibodies (IPA) has recently experienced a minor 3% dip in its stock price, which could present a potential buying opportunity for investors. Despite a negative Jensen Alpha of -0.52 and a net income loss of $26.6 million, the company has shown promising signs of growth with a quarterly revenue growth of 20.3%. Furthermore, with a revenue per share of $0.939, IPA's potential upside of 5.05 indicates that the company's stock could potentially increase in value in the future. Therefore, from a product viewpoint, investing in IPA could be a strategic move for investors looking to capitalize on the company's potential for growth.
Key Takeaways
Immunoprecise Antibodies holds a Market Volatility (Beta) of -1.02, indicating a significant risk relative to the market. As the market turns bullish, returns on Immunoprecise Antibodies are likely to decrease gradually. However, the company is expected to slightly outperform during market turmoil. Currently, Immunoprecise Antibodies has a negative expected return of -0.36%. It's crucial to review the company's maximum drawdown, daily balance of power, period momentum indicator, and the relationship between skewness and day typical price to determine if past performance will recur in the near future.Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Rifka Kats
Every cloud has a silver lining, and this rings true for the biotechnology sector, particularly for Immunoprecise Antibodies (IPA). The company, known for its significant contributions in the pharmaceuticals, biotechnology, and life sciences industries, has recently seen a minor dip of 3% in its stock price, defying the general market trend. This dip, however, could be perceived as a potential buying opportunity for discerning investors.
Immunoprecise Antibodies, traded under the primary ticker IPA.US on NASDAQ, has a market capitalization of $26.1 million as of the latest update on July 13, 2024. Despite reporting a loss of $26.6 million applicable to common shares, the company has shown promise with a quarterly revenue growth of 20.3%. This is indicative of the company's resilience and potential for recovery.
Analysts have given a strong buy consensus for IPA, with an estimated target price value of $7.99. This suggests a possible upside price of $4.02, further highlighting the investment opportunity. Despite the daily balance of power rating at -0.33, the accumulation distribution of 0.0918 signifies a healthy level of stock acquisition.
In conclusion, Immunoprecise Antibodies' recent dip could be a golden opportunity for investors. With the biotechnology industry's ever-growing relevance and the company's potential for growth, this might just be the right time to consider IPA. Currently, Immunoprecise Antibodies' average payables are projected to decrease significantly, based on recent years' reports. The current year's stock-based compensation to revenue is expected to grow to 0.14, while the market cap is forecasted to decline to approximately 191.2K. As the biotechnology sector garners investor interest, it's worth examining Immunoprecise Antibodies. We'll assess whether its shares are reasonably priced as we enter August. This article will also discuss key factors influencing Immunoprecise Antibodies' products and how they may affect the company's outlook for active traders this year.The performance of Immunoprecise Antibodies in the marketplace will significantly impact your decision to invest in its stock. Revenue growth, profitability, competitive positioning, management quality, and industry trends can influence Immunoprecise Antibodies' stock prices. When investing in Immunoprecise Antibodies, there are several factors to consider and potential outcomes to expect. As a company performs well, its stock price may increase, allowing investors to benefit from price appreciation. However, Immunoprecise Stock can experience significant price fluctuations due to market conditions, economic factors, industry trends, or company-specific news. This is why investing in stocks such as Immunoprecise Antibodies carries risks, including the potential for capital loss. Stock prices can decline, and investors may incur losses if they sell shares at a lower price than their initial investment.
Watch out for price decline
Please consider monitoring Immunoprecise Antibodies on a daily basis if you are holding a position in it. Immunoprecise Antibodies is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Immunoprecise Antibodies stock to be traded above the $1 level to remain listed. If Immunoprecise Antibodies stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
How important is Immunoprecise Antibodies's Liquidity
Immunoprecise Antibodies financial leverage refers to using borrowed capital as a funding source to finance Immunoprecise Antibodies ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Immunoprecise Antibodies financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Immunoprecise Antibodies' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Immunoprecise Antibodies' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Immunoprecise Antibodies's total debt and its cash.
Immunoprecise Antibodies Gross Profit
Immunoprecise Antibodies Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Immunoprecise Antibodies previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Immunoprecise Antibodies Gross Profit growth over the last 10 years. Please check Immunoprecise Antibodies' gross profit and other fundamental indicators for more details.
Going after Immunoprecise Financials
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Immunoprecise Antibodies has an asset utilization ratio of 26.56 percent. This suggests that the Company is making $0.27 for each dollar of assets. An increasing asset utilization means that Immunoprecise Antibodies is more efficient with each dollar of assets it utilizes for everyday operations.
As Warren Buffet once wisely noted, be fearful when others are greedy and greedy when others are fearful. Immunoprecise Antibodies (IPA), a key player in the healthcare and biotechnology sector, has recently seen a minor 3% dip in its stock price, defying the overall market trend. Despite reporting a loss of $0.35 per share for the current year and an operating income loss of $26.1M, the company's strong current ratio of 5.06X and a low debt to equity ratio of 0.02% indicate a robust financial health. With a market capitalization of $26.05M and a book value per share of 1.89X, this dip could present a potential buying opportunity for investors. The company's low beta of 0.26 also suggests less volatility compared to the market, making it a potentially safer bet in these uncertain times..
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Immunoprecise Antibodies. Please refer to our Terms of Use for any information regarding our disclosure principles.